Planned versus 'delivered' bladder dose reconstructed using solid and hollow organ models during prostate cancer IMRT.

BACKGROUND AND PURPOSE - All studies to date have evaluated the dosimetric effect of bladder deformation using an organ model that includes the dose to the urine. This research reconstructed bladder dose using both hollow and solid organ models, to determine if dose/volume differences exist.

MATERIALS AND METHODS - 35 prostate IMRT patients were selected, who had received 78Gy in 39 fractions and full bladder instructions. Biomechanical modelling and finite element analysis were used to reconstruct bladder dose (solid and hollow organ model) using every third CBCT throughout the treatment course.

RESULTS - Reconstructed dose (ReconDose) was 11.3Gy greater than planned dose (planDose) with a hollow bladder model (p<0.001) and 12.3Gy greater with a solid bladder model (p<0.0001). Median reconstructed volumes within the 30Gy, 65Gy and 78Gy isodoses were 3-4 times larger with the solid organ model (p<0.0001). The difference between planning bladder volume and median treatment volume was associated with the difference between the planDose and reconDose below 78Gy (R(2)>0.61).

CONCLUSIONS - Substantial differences exist between planned and reconstructed bladder dose, associated with the differences in bladder filling between planning and treatment. Dose reconstructed using a solid bladder model over-reports the volume of bladder within key isodose levels and overestimates the differences between planned and reconstructed dose. Dose reconstruction with a hollow organ model is recommended if the goal is to associate that dose with toxicity.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016 Apr 09 [Epub ahead of print]

Tara Rosewall, Janelle Wheat, Geoffrey Currie, Vickie Kong, Andrew J Bayley, Joanne Moseley, Peter Chung, Charles Catton, Tim Craig, Michael Milosevic

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada; Faculty of Science, Charles Sturt University, Australia.  Faculty of Science, Charles Sturt University, Australia; Faculty of Medicine and Health Sciences, Macquarie University, Australia., Faculty of Science, Charles Sturt University, Australia; Faculty of Medicine and Health Sciences, Macquarie University, Australia., Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada., Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada., Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada., Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada., Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada., Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada., Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Canada.